Safe Orthopaedics Past Earnings Performance

Past criteria checks 0/6

Safe Orthopaedics's earnings have been declining at an average annual rate of -2.8%, while the Medical Equipment industry saw earnings declining at 9.5% annually. Revenues have been growing at an average rate of 10.4% per year.

Key information

-2.8%

Earnings growth rate

100.0%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate10.4%
Return on equityn/a
Net Margin-118.8%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Safe Orthopaedics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0RAA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 226-790
30 Sep 226-790
30 Jun 225-690
31 Mar 225-790
31 Dec 215-790
30 Sep 214-890
30 Jun 214-980
31 Mar 214-980
31 Dec 204-880
30 Sep 204-870
30 Jun 204-770
31 Mar 205-870
31 Dec 195-880
30 Sep 194-880
30 Jun 194-780
31 Mar 194-770
31 Dec 183-670
30 Sep 183-670
30 Jun 183-660
31 Mar 183-660
31 Dec 173-760
30 Sep 173-660
30 Jun 173-660
31 Mar 173-660
31 Dec 162-660
30 Sep 162-770
30 Jun 162-770
31 Mar 162-770
31 Dec 152-770
30 Sep 152-660
30 Jun 152-560
31 Mar 152-560
31 Dec 142-550
30 Sep 142-440
30 Jun 142-440
31 Mar 141-430
31 Dec 131-330
31 Dec 120-330

Quality Earnings: 0RAA is currently unprofitable.

Growing Profit Margin: 0RAA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0RAA is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare 0RAA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0RAA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-12.2%).


Return on Equity

High ROE: 0RAA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/08 06:35
End of Day Share Price 2023/08/11 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Safe Orthopaedics SA is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arnaud RiverainGreenSome Finance
Martial DescouturesInvest Securities
Daniel AnizonInvest Securities